Comparative Effectiveness of Proton Therapy Versus Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Prostate Cancer
- Clinical Transformation
This project assesse whether proton therapy is associated improved health outcomes compared to photon chemoradiotherapy. Findings showed that proton chemoradiotherapy was associated a nearly two-thirds reduction in unplanned hospitalizations with similar disease-free and overall survival.
The use of concurrent chemoradiotherapies is a standard curative treatment for many cancers but is associated with substantial morbidity including hospitalizations during treatment. PC3I researchers conducted a study to assess whether proton therapy in the setting of concurrent chemoradiotherpy is associated with fewer 90-day unplanned hospitalizations or other adverse events and similar disease-free and overall survival compared to photon chemoradiotherapy. This was a retrospective non-randomized comparative effectiveness study.
Findings showed that proton chemoradiotherapy was associated a nearly two-thirds reduction in unplanned hospitalizations with similar disease-free and overall survival.
Penn Department of Radiation Oncology; Washington University in St. Louis Department of Radiation Oncology; Leonard Davis Institute of Health Economics; Penn Department of Biostatistics, Epidemiology, and Informatics; Abramson Cancer Center.
Project Leads
Project Team
-
Justin Bekelman
-
Peter Gabriel
-
Nandita Mitra
-
Peter O'Dwyer
-
Andrzej Wojcieszynski
